Table 3.

Local tolerability evaluations for all subjects during and at end of treatment

	Maximum severity during treatment		End-of-treatment severity (final score)
	Moderate	Severe	Moderate	Severe
A/BPO 0.3 % gel (N = 213)
Erythema	20	1	4	<1
Scaling	17	1	1	<1
Dryness	15	2	3	<1
Stinging/burning	19	6	1	1
A/BPO 0.1 % (N = 212)
Erythema	15	1	2	<1
Scaling	12	<1	2	0
Dryness	13	1	2	0
Stinging/burning	14	9	3	0
Vehicle gel (N = 68)
Erythema	6	1	1	0
Scaling	6	0	1	0
Dryness	4	1	1	0
Stinging/burning	3	1	0	0

Data are presented as  % of patients

A adapalene, BPO benzoyl peroxide